 DURHAM, N.C. PHILADELPHIA--BUSINESS WIRE--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical-stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform, and iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced a license and collaboration agreement under which iECURE plans to advance Precisions PBGENE-PCSK9 candidate into Phase 1 stud 